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Abstract 
Studied for decades, ionic liquids have largely been used as solvents in the pharmaceutical 
industry.  An active ionic liquid (AIL) contains an active pharmaceutical ingredient (API) as one 
of the counterions. They have to potential to be advantageous in traditional oral and alternative 
non-oral routes of administration. The library of successful AILs was increased with a series of 
generic and propriatary compounds.  They were characterized via infrared spectrometry, glass 
transition temperature, residual solvent, salt factor and biorelevant solubility. The impact of 
counterion selection on physical properties was discussed for three series of AILs. Issues with 
purification and the impact of residual solvent were investigated. While the equilibrium 
solubility enhancement of AILs over their neutral forms was not as high as hoped for, the 
dissolution rate advantage and utility for liquid dosing remains to be investigated. 
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Introduction 
Salt forms of pharmaceuticals can have a large impact on solubility, stability, manufacturing 
properties and ultimately bioavailability
1
. While resources can be devoted to finding the most 
stable polymorph of the chosen salt early in development, detrimental polymorphic changes can 
occur at any point in development and manufacture.  Polymorph screens and extended stability 
testing cannot account for all changes and stressors that a drug will encounter
2
. A low solubility 
phase can be developed by stabilizing the more soluble amorphous phase of the compound 
within a polymer matrix, called an amorphous solid dispersion. Major downsides to this method 
are the expensive manufacturing equipment needed, increased excipient loading in the product 
due to the polymer and the risk of crystallization from the meta-stable system
3
. The polymer 
matrix can temporarily stabilize the high energy amorphous phase, but many factors can induce 
nucleation and growth of crystal seeds like heat or moisture
3
.  A relatively new approach to 
increase solubility is to make a salt that is molten at room temperature, called an ionic liquid
1,2,4-6
.  
 
Technically, ionic liquids are salts that have a melting point below 100˚C. Of greater interest are 
room temperature ionic liquids (RTIL)
1,2,4-6
. As the name suggests, ionic liquids are defined by 
both their physical liquid state and a full ionic bond between the components.
7
 An investigation 
into the properties of ionic liquids shows an interesting relationship between entropy and 
enthalpy in determining the Gibbs free energy of fusion for the system, equation 1.
8
 
 
                                                           ΔfusG = ΔH – TΔS                                                             (1) 
Tm = ΔHm / ΔSm              (2) 
 
2 
 
 
The solid will undergo fusion (melt to form a liquid) when the ΔfusG = 0. When ΔfusG < 0, the 
liquid state is favored
9
. According to equation 2, the ratio of ΔHm over ΔSm must equal a 
temperature below 100˚C for an IL or below ambient temperature for a RTIL. Since the 
formation of a crystalline lattice would increase the order in the system and thus decrease the 
entropy, the role of entropy in eqs 1 & 2 is already in favor of a liquid. The stability increase in a 
crystalline phase comes primarily from the enthalpy term in the eq. 1. Enthalpy in the system can 
be controlled through decreasing the lattice energy by increasing the radii of the ions based on 
the Kapustinkii equation (equation 3) where UL = Lattice energy, K and d are constants, ν = 
number of ions in empirical formula, z = numbers of elementary charges on ions, r = radii of 
ions
10
.  
       (3) 
 
Decreasing symmetry in the ionic structure can also decrease crystallization tendency. Another 
approach to decrease crystallization tendency utilizes the importance of hydrogen bonding to 
create the crystal lattice. The phrase "anti-crystal engineering" was coined to describe actively 
picking cations and anions that will not form hydrogen bond donor and acceptor pairs and thus 
are more likely to form a stable IL
1
.   
 
Studied for decades, ionic liquids have largely been used as solvents in the pharmaceutical 
industry.  An active ionic liquid (AIL) contains an active pharmaceutical ingredient (API) as one 
of the counterions. They are potentially advantageous in traditional oral and alternative non-oral 
routes of administration. Just as the solubility of a crystalline salt can be modulated with the 
creative use of counter-ions, AILs have the potential of higher solubility than the parent 
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compound. By presenting the compound in a molten state in an oral formulation, problems of 
dissolution-rate limited absorption may be avoided, as with a liquid filled capsule. Their liquidity 
is well-suited for transdermal, intraoral, ocular, and intranasal administration. The current 
intellectual property environment has lead to increased importance of alternative administration 
routes as a means of extending exclusivity potentially past patent expiration
11
.   
 
There are risks involved in developing an AIL. Like amorphous compounds, the threat of 
crystallization should be evaluated through extensive phase and formulation stability testing
2
. 
The liquid phase is stable; however, crystalline solvates or cocrystals may form over time. Purity 
is also a concern with ionic liquids
12
. Solvent from the salt formation and absorbed atmospheric 
moisture are the most challenging to remove. Typically the crystallization step is used as a final 
purification step, removing impurities from the lattice
12
. Solid impurities are not removed in the 
creation of a crystal lattice for AILs. Crystalline salts are typically made with a slight excess of 
counterion to insure the reaction procedes to completion. A metathesis reaction, or double 
replacement reaction between two existing salts that exchange equimolar amount of counterion, 
to form an IL and an insoluble salt would allow the excess to be filtered from the IL product or 
isolated in a non-miscible organic phasea along with the insoluble by-product
12
. Impurities can 
inhibit crystallization, thus artificially forming an ionic liquid
10
. Due to the plasticizing effect of 
water and other solvents, all characterization data should be supplied with a reference to the 
dryness of the sample
10
. Viscosity can also be an issue with AILs that the proper choice of 
counter-ion can negate
2
. Not discussed in the literature, the difficulty of handling high viscosity 
liquids would need to be addressed before an AIL is chosen as a final phase. Equipment designed 
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to operate at elevated temperature with proper controls around water and temperature variation 
may be needed.  
 
The study of active ionic liquids to date mainly involves synthesis and limited physical 
characterization. Solubility claims have not been supported by empirical data.
1,2,4,5,13
. 
Furthermore, AILs have yet to be proven practically useful in industrial pharmaceutical 
development. Missing are comparisons of the AIL and crystalline salt forms by solubility in 
biorelevant media, solubility/miscibility in dosing vehicles, and bioavailability in preclinical 
species. Without head to head comparison, the advantages of AILs for drug delivery are all 
hypothetical. Very few actual pharmaceutical actives and counterions have been reported to 
make AILs
14
. The research herein aims to provide data to work towards an answer to the 
developability of active ionic liquids.  
 
For this research, two model AILs from the literature were made to gain an understanding of the 
synthesis and characterization of liquid actives before novel AILs were attempted. Propantheline 
tosylate and Lidocaine salicylate were chosen because of the availability of starting material and 
differing isolation procedures
1,6
. Then, the solubility in biorelevant GI media was compared to 
the parent forms, Propantheline Bromide and Lidocaine free base. Novel ionic liquids were 
attempted, first with lidocaine and then with other generic and Merck compounds. The current 
pool of counter-ions for IL formation consists of the sixty or so commonly used pharmaceutical 
salts and essentially all GRAS compounds capable of forming an ionic liquid with an API
15
. 
High throughput screening is necessary for active ionic liquids to become an available tool in salt 
selection for industrial pharma
16
. It was hypothesized that one could directly use or slightly 
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modify existing high throughput salt screens for AIL screening. The experimental methodology 
of an automated system in a 96-well plate was directly transferred to a medium through-put 
design. The "medium" descriptor indicates that all samples were manually aliquoted instead of 
using a robotic liquid handler. The screen was successfully developed on a 96-well plate and in 
total seven generic compounds and 11 Merck compounds were screened with benzoic acid, malic 
acid, mandelic acid, citric acid, and p-toluenesulfonic acid. Only this small subset of 
pharmaceutically acceptable acids was used in the screen, chosen by the following rationale. 
Toluenesulfonic acid was included because of past precedence in making an ionic liquid with 
propantheline. Citric acid is a common pharmaceutically acceptable counterion with a large ionic 
radius, which should decrease the likelihood of crystallization according to Kapustinkii equation.  
However it does have multiple hydrogen bond donors and acceptors in a symmetrical 
arrangement to stabilize a crystalline phase. Benzoic, mandelic, and malic acids are structually 
similar to salicylic acid, which is known to make an ionic liquid with lidocaine. They are all 
large ions compared to the most common pharmaceutical ions of chlorine and sodium
17
. 
Screening a series of phenyl carboxylic acid allows structure – property relationships to be 
investigated based on which ionic liquids are formed. 
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Experimental 
Chemicals used in the synthesis and characterization of AILs 
1.0 N hydrochloric acid, citric acid, glacial acetic acid, succinic acid, acetonitrile, acetone, 
dichloromethane, and 85% phophoric acid in water were purchased from Fisher Scientific. 
Tween 80, methanesulfonic acid, mandelic acid, malic acid, and fumaric acid were purchased 
from Acrōs Organics.  Lidocaine and itraconazole were purchased from Spectrum. Propantheline 
bromide was purchased from MP Biomedicals, LLC. SIF powder for biorelevant solubitliy was 
purchased from Phares. Ketoconazole was purchased from TCI. Piroxicam, lysine, 
acetominophen, tolfenamic acid, indomethacin, ketoprofen, p-toluenesulfonic acid, salicylic acid, 
nicotinic acid, glutamic acid, benzoic acid, and silver toluenesulfonate were purchased from 
Sigma Aldrich. All Merck propriatery compounds (MK-x) were synthesized by Merck Research 
Laboratories, Rahway, New Jersey.  
 
Analysis 
Differential Scanning Calorimetry  
Differential Scanning Calorimetry (DSC) experiments were run on a TA Instruments, New 
Castle, Delaware, Differential Scanning Calorimeter model Q2000-1086 in standard mode in a 
crimped aluminum pan, with an empty crimped aluminum pan as the reference. Experimental 
condition: Equilibrate at 25°C then ramp 10°C / min to 300°C. Data sampling occurred every 
0.20 sec/point.  
 
Modulated Differential Scanning Calorimetry 
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Modulated Differential Scanning Calorimetry (mDSC) experiments were run on a TA 
Instruments, New Castle, Delaware, Differential Scanning Calorimeter model Q2000-1086 in 
modulated mode in a crimped aluminum pan, with an empty crimped aluminum pan as the 
reference. Experimental condition: Equilibrate at -20°C; isothermal hold for 2 min.; modulate +/-
0.5°C every 60 sec; ramp 2°C /min to 100°C; mark end of cycle 1; ramp 5°C /min to -20°C; 
repeat isothermal hold and modulated ramp for two more cycles, with data sampling at 0.20 
sec/point. Cycle 1 data was reported. 
 
Thermogravimetric Analysis  
Thermogravimetric Analysis (TGA) analysis was performed on a TA Instruments, New Castle, 
Delaware, Thermogravimetric Analysis Infrared model Q5000-0288 using a ramp method, 
heating at 10.0°C /min from room temperature to 300°C or 500°C. Data was collected every 0.5 
sec, after the weight had stabilized. 
 
Dynamic Vapor Sorption 
Dynamic Vapor Sorption (DVS) analysis was run on a TA Instruments, New Castle, Delaware, 
Thermogravimetric Analysis Sorption Analysis model Q-5000-5059. The sample was dried at 
60°C until stabilized to 0.1% by weight for 5 min or a maximum dwell time of 60 min. The 
experiment for lidocaine salicylate and lidocaine benzoate were run at 25°C with an initial 
relative humidity (RH) of 5%, ramping to 95% RH and back to 5% RH in 5% increments after 
the sample stabilized to 0.1% for 5 min or a max dwell time of 180 min. The experiment for 
Propantheline tosylate was run at 40°C with an initial RH of 5%, ramping to 95% RH and back 
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to 5% RH in 5% increments after the sample stabilized to 0.1% for 5 min or a max dwell time of 
360 min. Data for both samples was collected every 5 sec.   
 
Equilibrium Solubility and Salt Factor 
Vehicle Preparation: Standard Gastric Fluid (SGF) was prepared by adding 2.0 g of sodium 
chloride and 16.8 mL of 1.0N HCl to a 1L bottle and diluting to 1.0 L with deionized water. 
Fasted State Simulated Intestinal Fluid (FaSSIF) was prepared by diluting 2.24 g of Phares 
Standard Intestinal Fluid (SIF) powder to 1.0 L of 30 mM phosphate buffer, pH 6.5. The buffer 
was prepared by adding 3.44 g of sodium dihydrogen phosphate, 0.420 g of solid socium 
hydroxide, and 6.20 g of sodium chloride to a 1 L bottle. The solids were dissolved with 1.0 L of 
deionized water. The 10% Tween 80 (TW80) vehicle was prepared by diluting 100 mL of TW80 
to 1.0 L with deionized water.  
 
Equilibrium solubility sample preparation: samples were heated on a 60°C hot plate for 10 min 
to increase flow, and then approximately 5 mg of salt was transferred to tarred 1.5 mL centrifuge 
tubes to which 100 μL of vehicle was added. The samples were mixed on a stir plate at 400 rpm, 
ambient temperature for 24 hours, with an interim measurement at 2 hours. At 2 hours and at 24 
hours, the samples were centrifuged at 21,100 xg using a Thermo Scientific, Waltham, 
Massachusetts, model Sorvall Legend Micro 21R centrifuge for 20 minutes.  To a 1.5 mL vial, 
10 μL of supernatant was transferred and 1000 μL of acetonitrile: water (1:1) diluent was added. 
The sample was mixed by inversion before injection.  All solubiltiy samples had a 101 dilution 
factor. For preparation of salt and active parent standards for weight based assay to determine the 
salt factor, approximately 2.5 mg of parent or salt was weighed into a tarrerd 25 mL volumetric 
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flask, then filled to volume with diluent of acetonitrile: water (1:1) and mixed on a stir plate 
overnight.  
 
High Performance Liquid Chromatography 
High Performance Liquid Chromatography (HPLC) analysis was performed using an Agilent, 
Santa Clara, California, model 1100 system. A 6 min gradient was used to resolve sample at 
40°C ramping from 10% acetonitrile, 90% (0.1% Phsophoric acid in water) to 90% acetonitrile 
in 5 min. The gradient was then decreased to 10% acetonitrile and held for 1 min. An Ascentis 
Fused Core, 4.6 x 100 mm, 2.7 μm particle size, C18 column was used. 
 
Rheometry 
Viscosity was measured with a TA Instruments, New Castle, Delaware, Rheometer model 
AR15000 with Rheology Advantage Control AR software and a 20 mm aluminum plate.  All 
samples were tested under a 500 um gap with the plate rotating from 0 π*rad/sec to 500 
π*rad/sec over 10 min. 
 
Fourier Transform Infrared Spectroscopy 
Attenuated Total Reflectance mode Fourier Transform Infrared Absorption (ATR FTIR) analysis 
was conducted with a Perkin Elmer, Waltham, Massachusetts, model Spectrum 100 FT-IR 
spectrometer. The analysis was performed between 515 cm
-1
 and 4000 cm
-1
 with three runs 
averaged to produce a spectrum.  
 
X-Ray Diffraction 
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X-Ray Diffraction (XRD) was performed using a Rigaku, The Woodlands, Texas, model 
Miniflex II XRD operating in reflectance mode, with data sampling every 0.02 °2θ with 1.0 sec 
per °2θ from 2.5° 2θ to 40° 2θ. Fixed mode operation at 30 kv and 15 mA. Integrated X-Ray 
Powder Diffraction Software, PDXL Qualitative analysis was used.  
 
Proton Nuclear Magentic Resonance Spectrometry 
Proton Nuclear Magentic Resonance (H
1
 NMR) spectra were collected on active ionic liquid 
samples and the active parent and counterions as reference using a Varian, Palo Alto, model 
Inova 400 MHz spectrometer using d
6
-dimethyl sulfoxide (DMSO) as solvent.  
 
Synthesis 
Propantehline Tosylate: Silver Halide Precipitation Method 
Propantehline tosylate was prepared on a 2.5 g scale via a methathesis reaction of Propantheline 
Bromide and silver p-toluenesulfonate
1
.  Starting material was mixed in 100 mL of methanol 
overnight, protected from light. The solids were filtered through 0.22 μm Millex Durapore PVDF 
syringe filters.  The majority of the solvent was removed via rotary evaporation, with the 
remaining solvent removed under high vacuum for 2 hours. The sample had solid amorphous and 
crystalline particles visible by polarized light microscopy. The sample was taken up in 10 mL of 
methanol and re-filtered through a new 0.22 um filter again into a round bottom flask. The flask 
was attached to a Büchi, Flawil, Switzerland, model Rotavapor R200 with the bottom of the flask 
imersed in a Buchi, Flawil, Switzerland, model B490 heating bath set to 40°C. The majority of 
the solvent was removed under a vacuum controlled by a KNF, Freiburg, Germany, model 
Neuberger Vacuum pump controller set to 20mBar. The vacuum was achieved using a KNF, 
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Freiburg, Germany, model Laboport Pump. The remaining solvent removed under 2mBar 
pressure vacuum for 2 hours. The sample was analyzed by mDSC, TGA, NMR, FTIR, rheometry, 
and DVS. Equilibrium solubility of the AIL and the active parent were measured.  
 
Lidocaine Salicylate: Hot Melt Method 
Lidocaine Salicylate was prepared on a 800 mg (Batch 1), then an 8 g (Batch 2) scale by adding 
equimolar amounts of Lidocaine and salicylic acid in 20mL scintillation vials, stirring the dry 
powder with a spatula to homogenize the mixture, and then heating to 100°C on a heated stir 
plate. In both batches, the mixture melted within 10min of heating to form a clear, viscous 
solution.  Upon cooling, the liquid increased in viscosity until effectively solid.  The samples 
were heated to 100°C on a hot plate to allow easier aliquots to be taken for modulated DSC and 
TGA (batch 2 only).   
 
Lidocaine Salicylate: Organic Extraction Method 
Lidocaine Salicylate was prepared on a 15 g scale (Batch 3), by adding molar equilivants of 
Lidocaine and salicylic acid to a 250 mL round bottom flask and dissolving the compounds in 
100mL of 1:1 acetone: water. The solution was stirred overnight using a IKA, Wilmington, 
North Carolina, RCT Basic stir plate with reaction vessel attachment at room temperature
6
. The 
sample was diluted with 100 mL of water then extracted with several washings of 
dichloromethane. The isolated organic layer was dried with about 5g of sodium sulfate 
transferred to a new round bottom flask. The flask was attached to a Büchi, Flawil, Switzerland, 
model Rotavapor R200 with the bottom of the flask imersed in a Buchi, Flawil, Switzerland, 
model B490 heating bath set to 40°C. The majority of the solvent was removed under a vacuum 
12 
 
 
controlled by a KNF, Freiburg, Germany, model Neuberger Vacuum pump controller set to 20 
mBar. The vacuum was achieved using a KNF, Freiburg, Germany, model Laboport Pump. 
Analysis was performed using mDSC, TGA, and DVS, FTIR and rheometry. H
1
 NMR spectra of 
starting material and sample collected. The sample was sent to an analytical department to test 
for residual solvent by Gas Chromatography (GC) and Karl Fisher Titration (KF). Based on GC 
and KF results, the sample was further dried under 2 mBar vacuum (Batch 3b). The glass 
transition temperature and residual solvent were remeasured. Equilibrium solubility of the AIL 
and the active parent were measured. 
 
Lidocaine based Ionic Liquids: Hot Melt Method 
Lidocainium benzoate, mandelate, malate, tosylate, nicotinate, and fumarate salts were prepared 
at an 800 mg scale by adding equimolar amounts of Lidocaine and counterion in the acidic form 
to 4 mL scintillation vials or 25 mL round bottomed flasks. The dry powder was stirred initially 
with a spatula to homogenize mixture. The mixtures were heated to 60°C on using an IKA, 
Wilmington, North Carolina, RCT Basic stir plate with reaction vessel attachment while stirring 
with a magentic stir bar. In the benzoate, mandelate, and malate samples, the mixture melted 
within 10min of heating to form a clear, viscous liquid.  The nicotinate, fumarate, and 
toluenesufonate samples did not form liquids. The liquid samples were analyzed using mDSC, 
TGA, FT-IR and rheometry.  The solid samples were analyzed using DSC, TGA, FTIR, and 
XRD. Equilibrium solubility of the AIL and the active parent were measured. 
 
Piroxicam, Tolfenamic Acid and Merck A: Organic Extraction Method 
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Samples were prepared on a 1 g scale by adding molar equilivants of both counterions in a 
250mL round bottom flask, and dissolving in 100 mL of solvent and stirring overnight at room 
temperature. The HCl salt of MK-A was reacted with glutamic acid, methanesulfonic acid, 
succinic acid, and sodium acetate, dissolved in acetonitrile. The neutral form of piroxicam was 
reacted with p-toluenesulfonic acid and citric acid as a solution in dichloromethane. Tolfenamic 
acid was reacted with L-lysine and lidocaine as a solution in 1:1 acetonitrile: water.  The samples 
were diluted with 100 mL of water then extracted with several washings of dichloromethane. 
The isolated organic layer was dried with about 5 g of sodium sulfate then filtered through celite 
into a round bottom flask. The flask was attached to a Büchi, Flawil, Switzerland, model 
Rotavapor R200 with the bottom of the flask imersed in a Buchi, Flawil, Switzerland, model 
B490 heating bath set to 40°C. The majority of the solvent was removed under a vacuum 
controlled by a KNF, Freiburg, Germany, model Neuberger Vacuum pump controller set to 20 
mBar. The vacuum was achieved using a KNF, Freiburg, Germany, model Laboport Pump.  The 
solid samples were analyzed using DSC, TGA, and XRD.  Spectra and graphs are located in the 
appendices.  
 
Medium Throughput Screen and Scale-up 
The basic compounds included in the screen were itraconazole, ketoconazole, and MK- B, C, D, 
E, G, H, J, K, and M. Three acidic generic compounds, acetominophen, indomethacin, and 
ketoprofen, and two Merck acidic compounds, MK-F and MK-L, were included as negative 
controls. The counterions are benzoic acid, mandelic acid, malic acid, p-toluenesulfonic acid, 
and citric acid.  Stock solutions of all active compounds and counterions were prepared at 0.1 M 
concentration in various solvents to allow for ease of transfer to well plates. All were prepared at 
14 
 
 
a 1:1 molar equilivant of active and counterion with 100 uL of each being added to a well.  The 
actives are listed in Table 1 along with the solvents used and screening hits. The plates were 
mixed on a shaker/mixer for 30 min, and then the solvent was evaporated in a fume hood 
overnight. A hit was defined as a sample having no visible solids after evaporation.  They are 
labeled "L" in Table 1, while samples with visible solids are labeled "S". Hits for MK-C, MK-D, 
MK-B, acetominophen, and itraconazole were repeated at a larger scale.  Due to limited 
compound availability and numerous hits, MK-C was only scaled up to 50 mg active samples.  
The others were scaled up to 0.5 g – 1.0 g active samples. These batches were prepared 
identically to the screening samples.  Compound and acid were added in equimolar amounts to 
either 4 or 20 mL scintillation vials, dissolved with solvent and heated to 60°C using an IKA, 
Wilmington, North Carolina, RCT Basic stir plate with reaction vessel attachment to allow for 
evaporation of solvent. DSC was performed on samples with visible solids while mDSC and 
TGA were performed on the potential ionic liquids.  The results from the scale up are in Table 2. 
Samples with solids have an indicated melting point and samples that were potential ionic liquids 
have a glass transition temperature (Tg) listed. Equilibrium solubility of the AIL and the active 
parent, except for ketoprofen, were measured. 
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Results 
Medium Throughput Screen 
The AILs medium throughput screen was implemented for a total of 16 generic and Merck 
compounds. Acetominophen, indomethacin, ketoprofen, MK-F and MK-L are acidic compounds, 
which were included in the screen as negative controls.  Active compound and counterion 
structures of all samples are depicted in Figure 1. Since there are numerous scenarios that 
produce a liquid, such as impurities, excess solvent, hydrogen bonding, and mixtures of ionic and 
hydrogen bonding, the ability of the screen to produce all these products needs to be known
18
. 
Precipitated solids, labeled “S” in Table 1, were obvious by observing small particles or crystals 
growing in the wells. Samples that were deemed hits were scaled up and labeled “L” in the table. 
Abbreviations for the counterions used in Table 1 are as follows: counterions (CI), benzoic acid 
(BA), malic acid (MA), p-toluenesulfonic acid (TsA), mandelic acid (MdA), and citric acid (CA). 
The 1 g samples of Merck K tosylate, Merck J tosylate, all Merck H salt hits, and ketoconazole 
benzoate produced solids and no further characterization was conducted.  
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Active Compounds 
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Merck Propriatary Active Compounds 
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Acidic Counterions  
 
Acidic Active and Basic Counterion 
                       
                                    Tolfenamic Acid                                        Lysine 
 
Figure 1. Active compounds and counterions. * Acids used in medium throughput screen.                   
    Negative control active acidic compounds not expected to form an ionic bond with acidic 
counterions. 
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Indomethacin, MK-F and MK-L, all acidic parent compounds, did not produce hits in the screen. 
Acetominophen tosylate and ketoprofen malate, mandelate, and tosylate did result in screen hits.  
When reacted at a 1g scale, the acetominophen tosylate formed a crystalline solid.  The 
ketoprofen salts formed meta-stable liquids that all eventually crystallized after several weeks of 
ambient storage. This was predicted in the tosylate salt from the melting endotherm present at 
77°C. The 1.0 g scale of MK-A salts were all crystalline with the melting point listed in Table 2.  
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Table 1. Medium Throughput Screen with Results: L = Liquid and S = Solid 
 CI BA MA TsA MdA CA 
Parent 
Compound 
pKa 4.2 3.5, 5.1 -1.34 3.37 3.1, 4.8 
MK-B 4, 4.5, 13 S S L S S 
       
MK-F 5.37 S S S S S 
       
MK-G 5.6, 10.4 S S S S S 
       
MK-C 11.68 L L L L L 
       
Acetominophen 9.5 S S L S S 
       
Ketoprofen 4.0-4.5 S L L L S 
       
Indomethacin 4.5 S S S S S 
       
Ketoconazole 2.9, 6.5 L L L L L 
       
Itraconazole 3.7 S S L S S 
       
MK-H 12.7 L L L L L 
       
MK-J 3.3, 9.9, 13.8 S S L S S 
       
MK- K 1.2, 3.2, 12.0 S S L S S 
       
MK-L 4.5, 11.1, 12.7 S S S S S 
       
MK-M 3.0, 9.4 S S S S S 
       
MK-E 4.9, 13.6 L L L L L 
       
MK-D 5.3, 7.5 S S L S S 
       
L = Liquid; S = Solid 
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Glass Transition Temperature  
The glass transition temperatures (Tg) after the first cycle of mDSC or the melting points are 
listed in Table 2 for all measured samples with the plots located in Appendices A and B, 
respectively. The Tg of the prepared lidocaine salicylate samples differ from the literature 
sample
6
.  A likely reason is the different amounts of residual solvents and/or water in the 
samples, as discussed above. Water is a plasticizer for amorphous systems, which would explain 
why a system with more water, like batch 3 vs. 3b, would have a lower Tg. The literature sample 
of Propantheline tosylate has a Tg of 7°C, while the sample prepared in these experiments had a 
Tg of -4.5°C, a 11.5°C decrease. Like the Lidocaine salicylate, the differences in the Tg of the 
two samples may be related to differing levels of residual solvent in the systems. MK-B tosylate 
exhibits a 22°C glass transition and then a small endotherm at 90°C that may represent a 
heterogeneaity in the sample or that the sample is becoming ordered upon heating, leading to a 
melting event. MK-E tosylate and citrate salts exibit similar behavior upon heating. The tosyalte 
salt has two glass transitions at 18.51°C and 41.76°C.  The citrate salt has three at 22.31°C, 
41.25°C, and 77.56°C. The MK-C tosylate and citrate salts as well as the ketoconazole 
mandelate and malate salts have glass transitions that are at or slightly above room temperature.   
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Table 2. Percent weight loss by 100°C (RS), Glass Transition Temperature (Tg) and Melting 
Points (Tm) of Attempted Active Ionic Liquids 
Sample RS (%) Tg (°C) Tm (°C) 
Lidocaine Salicylate (1) NM 14.30  
Lidocaine Salicylate (2) 0.1959 16.74  
Lidocaine Salicylate (3) 3.431 -11.66  
Lidocaine Salicylate (3b) 0.2691 -3.28  
Lidocaine Benzoate 0.9749 -22.92  
Lidocaine Malate 2.309 19.94  
Lidocaine Mandelate 0.5051 3.18  
Lidocaine Tosylate 0.366  150.76 
Lidocaine Nicotinate 0.3228  59.95 
Lidocaine Fumarate 0.2888  67.98 
Propantheline Tosylate 0.8685 -4.51  
Tolfenamic Lysine NM  212 
Tolfenamic Lidocaine NM  96 
MK-A Glutamate 2.298  106.62 
MK-A Mesylate 5.459  171.21 
MK-A Acetate NM  188.08 
MK-A Salicylate 3.022  158.5 
Piroxicam Citrate NM  153.08 
Piroxicam Tosylate NM  114.06 
MK-B Tosylate 4.285 21.95 89.98 
MK-C Benzoate 0.6524 -5.8   
MK-C Malate 1.107 -26   
MK-C Tosylate 1.1245 
20.21 
71.47   
MK-C Mandelate 0.5529 
9.96 
75.96   
MK-C Citrate 0.2145 
18.21 
59.54 
84.63   
MK-C Benzoate 0.6524 -5.8  
MK-C Malate 1.107 -26  
MK-C Tosylate 1.1245 20  
MK-C Mandelate 0.5529 10  
MK-C Citrate 0.2145 17  
Acetominophen Tosylate 0.9585  122.7 
Itraconazole Tosyate 0.5748  92.37 
MK-D Tosylate NM  111.19 
Ketoconazole Malate 0.5838 23.40  
Ketoconazole Tosylate 0.5119 14.84  
Ketoconazole Mandelate 0.1919 31.60  
Ketoconazole Citrate 0.1648 11.86  
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Ketoprofen Malate** 1.064 -6.02  
Ketoprofen Tosylate** 1.878  77.22 
Ketoprofen Mandelate** 0.6161 -14.39  
MK-E Benzoate 0.6305 6.84  
MK-E Malate 1.322 7.97  
MK-E Tosylate 1.717 
18.51 
41.76  
MK-E Mandelate 1.047 6.88  
MK-E Citrate 0.8619 
22.31 
41.25 
77.56  
        NM = Not Measured 
                   **Samples crystallized during of benchtop storage.  
  
Viscosity 
The viscous nature of the lidocaine salicylate, malate, and mandelate and propantheline tosylate 
were revealed through a series of rheometric studies at increasing temperatures. The viscosities 
of these samples tested are listed in Table 3, with additional data in Appendix E. Lidocaine 
salicylate is practically a solid at room temperature, with a viscosity of 8.05*10
5  
Pa*s.  A portion 
of sample stuck to the side of a round bottom flask would take several hours to flow to the 
bottom of the flask. The rheometry method was set so the plate rotated at increasing speed, from 
0 to 500 rad/s.  At 22°C, the plate rotation rate could only increase from 0 to 0.19 rad/s. When 
the temperature is increased to 40°C, the plate rotation rate only increased to 31 rad/s. The 
temperature had to be raised to 60°C for the plate to reach the desired 500 rad/s spin rate. Even at 
60°C, the material has a viscosity of 81.6 Pa*s.  At 80°C, the material thins to a flowable 5.4 
Pa*s. For reference, honey has a reported viscosity of 2-10 Pa*s
19
.  Lidocaine benzoate’s 
viscosity is 28.76 Pa*s at 22°C and 3.09 Pa*s at 40°C.  Lidocaine mandelate has a viscosity of 
7280 Pa*s at 22°C and 8.2 Pa*s at 80°C. The malate salt is the most viscous lidocaine AIL made 
with a viscosity of 77.82 Pa*s at 80°C. The propantheline tosylate data tracks with the lidocaine 
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data except for the order of magnitude lower viscosity at 22 ˚C as compared to 40 ˚C. The cause 
of this anomaly is unknown.  
Table 3. Viscosity at various temperatures for four Active Ionic Liquids 
  Viscosity (Pa*s) 
T (˚C) Propantheline 
Tosylate 
Lidocaine 
Malate 
Lidocaine 
Mandelate 
Lidocaine 
Salicylate 
Lidocaine 
Benzoate 
22 410.1 NM 7280 8.09E+05 28.76 
40 5558 NM 129.1 4571 3.09 
60 314.6 830.2 8.26 81.60 NM 
80 19.27 77.82 NM 5.4 NM 
     NM = Not Measured 
 
 Fourier Transform Infrared Spectroscopy 
Attenuated total reflectance Fourier transform infrared spectroscopy was used to analyze the 
ionic liquid samples and the parent compounds. The peak tables are listed in the Table 4.  The 
spectra of lidocaine benzoate overlaid with its parent compounds is in Figure 2. All other spectra 
are in Appendix G.  
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Figure 2. Lidocaine standard (red), Benzoic acid standard (black), and Lidociane benzoate (blue) 
overlaid IR spectra. 
 
Table 4. Identifying Peaks for Salt Formation of Lidocaine Ionic Liquids 
  Lidocaine 
Salicylate 
Lidocaine 
Benzoate 
Lidocaine 
Mandelate 
Lidocaine 
Malate 
Peak 
wave-
number 
(cm^-1) 
Lidocaine Salt Acid Salt Acid Salt Acid Salt Acid 
COOH   1655  1678  1705  1689 
COO-  1626  1600  1600  1590  
          
COOH   1382  1419  1452  1410 
COO-  1378  1376  1355  1375  
          
C-N 
stretch 
1490         
C-N 
stretch 
ionized 
 1483  1475  1472  1471  
  1456  1449  1451  1420  
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Nuclear Magnetic Resonance  
The proton Nuclear Magnetic Resonance (H
1 
NMR) spectra are in Appendix D. The peak lists 
for lidocaine salicylate and propantheline tosylate compared to the literature values are below in 
Table 5. The spectra of lidocaine benzoate, malate and mandelate salts are the same as the parent 
spectra.  
Table 5. H
1 
NMR Spectra for Lidocaine Salicylate and Propantheline Tosylate 
Lidocane Salicylate, H
1
 NMR 400Hz 
Literature Experimental 
10.05 (br s 1H) 9.9 (br, s, 1H) 
7.72 (dd, J1=7.75hz;  
\J2=1.8Hz, 1H) 7.72 (dd, 1H 
7.24 (m, 1H) 7.3 (m, 1H) 
7.09 (s, 3H) 7.1 (s, 3or 4H) 
6.70 (m, 2H) 6.7 (m, 2H) 
3.98 (s, 2H) 3.9 (s, 2H) 
3.10 (q, J=7.28Hz, 4H) 3.1 (q, 4H) 
2.16 (s, 6H) 2.2 ((s, 6H) 
1.22 (t, J=7.34Hz, 6H) 1.2 (t, 6H) 
  
Propantheline Tosylate, H
1
 NMR 400Hz 
Literature Experimental 
1.14-1.18 (t, 12H) 1.15-1.19 (t, 12H) 
2.29 (s, 3H) 2.24 (s, 3H) 
2.66 (s, 3H) 2.65 (s, 3H) 
3.42-3.45 (t(b) 2H) 3.42 (t, 2H) 
3.70-3.79 (m, 2H) 3.7-3.8 (m, 2H) 
4.36-4.39 (t(b), 2H) 4.4 (t, 2H) 
5.31 (s, 1H) 5.32 (s, 1H) 
7.09-7.12 (m, 2H) 
7.1-7.23 (m, 6H) 7.12-7.22 (m, 4H) 
7.39-7.40 (m, 4H) 
7.35-7.5 (m, 6H) 7.46 - 7.49 (m, 2H) 
 
X-Ray Powder Diffraction 
X-ray spectra overlays of lidocaine with the attempted tosylate, fumarate, and nicotinate salts 
revealed that salt formation did not take place because the product has the same XRD spectra as 
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the parent compound. The lidocaine nicotinate sample XRD pattern overlaid with lidocaine free 
base is in Figure 3. The XRD pattern overlays for the other listed samples are in Appendix F.  
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Figure 3. Lidocaine with nicotinic acid sample (pink) and lidocaine standard (red) XRD patterns.  
 
Physical Stability 
The lidocaine salicylate, benzoate, malate, and mandelate ionic liquids are physically stable for 
at least 20 months with benchtop storage. They are clear to slightly yellow in color. Merck C 
AILs are clear but the MK- E AILs are yellow colored.  The Ketoconazole AILs are dark red but 
still transparent. MK-B, MK- C, MK- E, and Ketoconazole AILs are physically stable for at least 
9 months. The ketoprofen salts crystallized after 1-3 weeks at benchtop conditions. The second 
endotherm of MK-B tosylate at 90°C is indicitative of a crystallization risk, as are the 
heterogenous systems of MK-E tosylate and citrate.  
 
Residual Solvent  
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TGA was used to determine total amount of RS remaining in the sample after vacuum drying. 
Without the attachment of a mass spectroscopy unit, the identity of solvent evaporating over time 
could not be determined. The amount of total solvent lost by 100°C after a 10°C/min ramp for all 
the samples tested is listed in Table 2. Samples prepared in a 4 mL or 20 mL round bottom flask 
were dried to less than 6% total solvent by heating under a vacuum. Further drying was not 
needed for the samples that were scale-ups from screen hits. By TGA analysis, 3.43 weight % of 
solvent was lost from the lidocaine salicylate sample 3 by 100°C, including acetone, water, and 
DCM. The water analysis by Karl Fisher titration determined that there was 2 % by weight 
absorbed by the sample. Analysis by gas chromatography detected 0.25 % by weight of acetone 
and dichloromethane. Adding the KF and GC solvent amounts together give a total solvent 
amount of 2.25 weight %, which is 1.18 % by weight lower than the total determined from TGA 
weight loss upon heating. As this sample is quite hygroscopic (see DVS results), the absorbed 
moisture may be a dynamic amount reflecting the ambient humidity of the sample storage 
conditions. Further drying at 5mBar (sample 3b) resulted in 0.26 % by weight lost upon heating 
to 100°C. 
 
Hygroscopicity  
The plots of humidity absorption/desorption of lidocaine salicylate, propanthline tosylate, and 
lidocaine benzoate are in Appendix C. Figure 4 is a plot of the lidocaine salicylate % by weight 
of water absorbed vs. time. The plot compares weight % vs time to relative humidity vs. time so 
that it is easily observable that the sample did not reach equilibrium between humidity increases. 
The sorption plot for Lidocaine Salicylate did not show significant water sorption until 
conditions greater than 80% RH. However, weight stabilization was not achieved within the 
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designated 180 min before the between humidity increases, suggesting that the sample may be 
more hygroscopic than the experimental conditions can determine. The water sorption data for 
propantheline tosylate was collected with a longer maximum dwell time of 360 min.  The 
sorption plot is as expected for an AIL. Propantheline tosylate is a hygroscopic compound, 
gaining 5% by weight upon reaching 60% RH and over 20 % by weight upon reaching 95% RH. 
The water sorption is completely reversible upon dehumidification. Lidocaine benzoate is also 
highly hygroscopic. The reversible water adsorption of 30% by weight upon reaching 95% RH 
occurs mostly between 60% and 95% RH.  
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Figure 4. Plot of the percent weight gain by lidocaine salicylate batch 3b sample vs. time (blue 
line) and the measured relative humidity of the sample chamber vs. time (green line).  
 
 
Salt Factor and Solubility 
Twenty samples were tested for the percentage of parent compound in the sample and 15 of 
those samples had less than 10% difference in measured percentage and calculated for a mono-
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salt, after correcting for residual solvent as measured by TGA. Five samples had a greater than 
10% difference from the calculated mono-salt stoichiometry. All are listed in Table 6 with their 
aqueous and biorelevant solubilities. 
Table 6. Salt Factor of ionic liquids and Solubility of ioinc liquids compared to free form at 2 
and 24 hours. 
      
Free base equilivants 
(mg/mL) 
Sample Vehicle Salt Factor 2 h 24 h (pH) 
Lidocaine Water   NM NM (NM) 
Lidocaine SGF   NM 11.0* (NM) 
Lidocaine FaSSIF   NM 11.7* (NM) 
Lidocaine 10%TW80   NM 24.6* (NM) 
Lidocaine Salicylate Water 1.57 55.6 27.4 (5.85) 
Lidocaine Salicylate SGF   57.5 34.8 (5.52) 
Lidocaine Salicylate FaSSIF   51.9 32.2 (5.8) 
Lidocaine Salicylate 10%TW80   110 131 (5.79) 
Lidocaine Benzoate Water 1.62 51.8* 51.3* (5.91) 
Lidocaine Benzoate SGF   32.1* 31.7* (5.11) 
Lidocaine Benzoate FaSSIF   28.2* 29.8 (6.11) 
Lidocaine Benzoate 10%TW80   67.0* 66.9* (6.08) 
Lidocaine Malate Water 1.70 43.5* 43.0* (4.14) 
Lidocaine Malate SGF   102* 103* (4.06) 
Lidocaine Malate FaSSIF   63.2* 60 (4.15) 
Lidocaine Malate 10%TW80   129* 144* (4.16) 
Lidocaine Mandelate Water 1.18 49.7* 48.8* (5.19) 
Lidocaine Mandelate SGF   37.0* 34.9 (4.11) 
Lidocaine Mandelate FaSSIF   123* 133* (5.74) 
Lidocaine Mandelate 10%TW80   51.7* 106* (5.38) 
MK-C Water   NM NM (NM) 
MK-C SGF   NM 1.60* (NM) 
MK-C FaSSIF   NM 1.20* (NM) 
MK-C 10%TW80   NM 20.0* (NM) 
MK-C Malate Water 1.36 1.56 1.41 (2.54) 
MK-C Malate SGF   1.39 1.21 (1.88) 
MK-C Malate FaSSIF   1.45 1.02 (2.92) 
MK-C Malate 10%TW80   5.67 11.8 (2.84) 
MK-C Mandelate Water 1.31 1.24* 1.16 (3.02) 
MK-C Mandelate SGF   1.26* 1.15 (1.93) 
MK-C Mandelate FaSSIF   1.29* 0.95 (6.15) 
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MK-C Mandelate 10%TW80   11.0* 13.6* (3.2) 
MK-C Citrate Water 1.19 1.61 1.43 (2.32) 
MK-C Citrate SGF   1.44 1.3 (1.91) 
MK-C Citrate FaSSIF   1.48 1.37 (2.48) 
MK-C Citrate 10%TW80   17.5 19 (2.53) 
MK-C Tosylate Water 10.61 0.921* 1.08 (2.37) 
MK-C Tosylate SGF   0.663* 0.75 (1.62) 
MK-C Tosylate FaSSIF   0.847* 0.81 (5.84) 
MK-C Tosylate 10%TW80   2.03* 1.52 (2.4) 
Ketoconazole Malate Water 1.29 21.2 12.5 (3.49) 
Ketoconazole Malate SGF   16.4* 18.2 (3.4) 
Ketoconazole Malate FaSSIF   10.5 6.43 (3.55) 
Ketoconazole Malate 10%TW80   25.7* 27.5 (3.81) 
Ketoconazole Tosylate Water 1.32 7.47* 6.86 (3.55) 
Ketoconazole Tosylate SGF   17.6 15.8 (3.2) 
Ketoconazole Tosylate FaSSIF   6.20 3.88 (3.65) 
Ketoconazole Tosylate 10%TW80   34.7 34.7 (4.05) 
Ketoconazole Mandelate Water 1.26 12.1 9.56 (3.72) 
Ketoconazole Mandelate SGF   15.9 14.6 (3.73) 
Ketoconazole Mandelate FaSSIF   11.1 4.77 (3.82) 
Ketoconazole Mandelate 10%TW80   35.7 41.4 (4.29) 
Ketoconazole Citrate Water 1.43 28.8* 21.2 (3.77) 
Ketoconazole Citrate SGF   25.6* 26.4* (3.66) 
Ketoconazole Citrate FaSSIF   23.4 20 (3.95) 
Ketoconazole Citrate 10%TW80   28.3* 29.7* (3.87) 
* Threshold Equilibrium 
Value 
NM = Not Measured         
 
    
 
Discussion 
It is expected that a screen without a purification or assisted evaporation step would tend towards 
false positives as small amounts of residual solvent can have a major impact on solubility of 
these compounds.  It was observed that in particular the p-toluenesulfonic acid when dispensed 
from a THF stock seemed to create more false positives than the acids in methanol stock. There 
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were eleven total tosylate hits and six of those compounds did not have a screen hit with any 
other acid. Only one of these tosylate hits were scaled up to produce a stable ionic liquid.  In the 
future, it is suggested that the same solvent be used for all stock solutions to mitigate a bias in the 
screen results.  
 
MK- C, an amorphous free base compound, resulted in successful scaled up hits for ionic liquids 
for almost every acid tested.  This opens up a new opportunity for amorphous compounds, which 
can have physical properties that are difficult to control.  A stable liquid salt may be used instead 
of developing a solid dispersion to stabilize the metastable amorphous phase. When considering 
that multiple AILs can be made with lidocaine and MK- C, there may be trends that if a single 
ionic liquid phase can be found for a compound, several are likely to form.  This supports the 
literature claims of tunable physical properties based on the counterion
5
. The Tg’s of the MK-C 
AILs compare as follows: malate < benzoate < mandelate < citrate < tosylate.  All have a glass 
transition temperature that is less than room temperature, although the citrate and tosylate salts 
only just below.   
 
The trend of malate, benzoate and mandelate producing lower Tg AILs than citrate and tosylate 
continues with MK-E.  The Tg’s for the malate, benzoate and mandelate salts are all about the 
same, but the citrate and tosylate salts have multiple Tg’s with the lowest of each being at the 
edge of room temperature.  
 
The lidocaine properties follow a similar trend. Lidocaine formed benzoate, malate and 
mandelate AILs, but a solid tosylate salt was formed with lidocaine (citrate was not tested).  
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Tosylate AILs were successfully formed with propantheline and ketoconazole, so the very low 
pKa acid is still relevant for AILs screening. Nicotinic acid is a carboxylic acid that is 
structurally similar to benzoic acid and mandelic acid, but with a substituted pyridine instead of a 
substituted phenyl ring. Its pKa is 3.4, which is almost exactly the same as mandelic acid, pKa 
3.37.  Both suggest that it should form an ionic liquid with lidocaine. However, nicotinic acid did 
not react with lidocaine via the melt procedure.  A solvent-mediated method wherein the two 
parent compounds are fully dissolved may facilitate reaction.  Similarly, the fumaric acid sample 
did not react with lidocaine.  Fumaric acid is a reduced structure compared to malic acid with 
one unsaturation. A possible reason that it wouldn't form a salt with lidocaine is perhaps that the 
trans configuration is prohibitive to the steric arrangement needed for ionic bonding. The pKa of 
fumaric acid is 3.03 – slightly lower than malic acid's 3.46 pKa.  Like with the nicotinic acid, 
performing the reaction under fully dissolved conditions may facilitate salt formation.  The 
melting point of these two acids adds to this postulation.  Nicotinic and fumaric acids both have 
melting points greater than 200°C, but benzoic, mandelic, and malic acid all have melting points 
in the between 110-130°C. The temperature of the reaction vessel never increased enough to 
melt the acid and commence salt formation.  Therefore, there is potential that if the reaction was 
performed using the solvent extraction method for the lidocaine salicylate batch 3, that a salt 
would form, liquid or solid
6
. The dual active AIL attempt with lidocaine and tolfenamic acid 
resulted in crystals suspended in a viscous liquid.  It may be that lidocaine formed a non-mono 
salt with the tolfenamic acid, so there was excess tolfenamic acid left to recrystallize.  This 
reaction also warrants further process development. 
 
Proton Transfer Identification 
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Several key articles have already discussed the changes in IR spectra in salicylic acid, benzoic 
acid, malic acid, mandelic acid and lidocaine upon salt formation
20-26
. The extent of carboxylate 
ionization in salicylic acid modulates both antisymmetrical and symmetrical stretching of the 
bonds
27
. When protonated, the antisymmetical peak of the carboxylate appears between 1650 cm
-
1
 and 1750 cm
-1
.  The salicylic acid sample measured as a reference is within that range at 1655 
cm
-1
. The lidocaine salicylate sample exhibits a carboxyl antisymmetric peak shift to 1626 cm
-1
.  
This indicates that there is ionic character at this acidic group.  Bica, et al.
28
 used the lack of a 
shift at this peak to prove that they had made a lidocaine–fatty acid melted co-crystal instead of 
an ionic liquid
28
. This peak has also been used as a key difference in the sodium salicylate vs. 
salicylic acid
22
.  There the ionized carboxyl peak only shifted down about 8 cm
-1
 from 1660 to 
1652 cm
-1 
upon salt formation.  The symmetrical stretching of the carboxyl peak is also affected 
by the proton transfer in lidocaine salicylate
27
.  The peak shifts from 1382 cm
-1
 in the acidic form 
to 1378 cm
-1
 in the deprotonated state of the salt.  The evidence for proton transfer is further 
inhanced by the lidocaine amide peak.  In the free base spectrum, the carbonyl group of the 
amide has one peak at 1490 cm
-1
, but in lidocaine salicylate, there are two peaks at 1486 cm
-1
 
and 1456 cm
-1
.  This was also observed in comparing lidocaine to its hydrochloride salt
21
. The 
peaks are attributed to the carbonyl group of the amide stretching. There are two bands in the salt 
form because the stretching is no longer equilivant in the two C-N bonds upon ionization. Based 
on the ionized carboxyl peak alone, lidocaine saliclyate can be classified as an ionic liquid, with 
the other peak shifts serving as further support. IR can be used to identify the ionic nature of 
newly prepared liquid systems.   
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As all the successful lidocaine salt formations were with carboxylic acids, the peaks of interest 
are from the same functional groups as were analyzed for lidocaine salicylate.  The lidocaine 
benzoate sample had the antisymmetric stretching carboxyl peak shift from 1678 cm
-1 
in the 
acidic form to 1600 cm
-1 
in the ionized form
23
.  Also, the symmetric stretching carboxyl peak 
shifted from 1419 cm
-1 
in the acidic parent to 1376 cm
-1 
in the ionized lidocaine salt.  The 
carbonyl group of the amide in the lidocaine salt became the two peaks at 1475 and 1449 cm
-1
, 
split from the single peak at 1490 in the lidocaine free base.  These three shifts suggest that the 
proton from the carboxyl group of benzoic acid has transferred to the amide group in lidocaine, 
forming lidocaine benzoate salt.  
 
The formation of the lidocaine mandelate salt can be supported by the antisymmetric stretching 
carboxyl peak shift from 1705 cm
-1 
in mandelic acid to 1600 cm
-1 
in the lidocaine salt
24,26
.  The 
corresponding symmetric stretching carboxyl peak shifted from 1452 cm
-1 
in mandelic acid to 
1355 cm
-1 
in the lidocaine salt.  The carbonyl group of the amide in the lidocaine salt became the 
two peaks at 1472 and 1451 cm
-1
, split from the single peak at 1490 in the lidocaine free base.  
These three shifts suggest that the proton from the carboxyl group of mandelic acid has 
transferred to the tertiary amine group in lidocaine, forming lidocaine mandelate salt.  
 
The lidocaine malate salt can be identified by the antisymmetric stretching carboxyl peak shift 
from 1689 cm
-1 
in malic acid to 1590 cm
-1 
in the lidocaine salt
25
.  The corresponding symmetric 
stretching carboxyl peak shifted from 1410 cm
-1 
in malic acid to 1375 cm
-1 
in the lidocaine salt.  
The carbonyl group of the amide in the lidocaine salt became the two peaks at 1471 and 1420 
cm
-1
, split from the single peak at 1490 cm
-1
in the lidocaine free base.  These three shifts suggest 
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that the lidocaine malate salt was formed by the proton from the carboxyl group of malic acid 
transferring to the tertiary amine group in lidocaine.  
 
The NMR spectrum of lidocaine salicylate suggests that a material of the same composition as in 
Bica et.al was prepared
6
. The quaternary peak at 3.1 ppm corresponding to the four ethyl protons 
adjacent to the tertiary amine and the single peak at 3.9 ppm corresponding to the two methylene 
protons between the amide and the tertiary amine in the lidocaine salicylate sample are shifted to 
a higher frequency relative to the lidocaine sample, which has a corresponding quaternary peak 
at 2.6 ppm and a single peak at 3.2 ppm, respectively. The addition of a proton at this tertiary 
amine would produce a shift in peaks for these neighboring protons. There is a shift in the phenyl 
proton ortho to the carboxylic acid in salicylic acid when that carboxylic acid ionizes.  The 
multi-peak for the single hydrogen is located at 7.5 ppm when the carboxylate is acidic.  Once 
ionized, the peak shifted to 7.3 ppm for lidocaine salicylate. The NMR data compliments the IR 
data in pointing to a proton transfer from the carboxylic acid in salicylic acid to the tertiary 
amine in lidocaine forming an ionic salt.  
 
The NMR spectral data of the Propantheline tosylate sample matched the literature data and 
indicated that the sample was not a physical mixture of the two starting components
1
.  It was also 
essentially identical to the Propantheline bromide starting material.  The tosylate's phenyl 
protons are not apparent in the ionic liquid spectra. The NMR spectra of the other three lidocaine 
ionic liquids did not show shifts from the lidocaine free base spectra.  The samples are dissolved 
in d
6
-DMSO, potentially disproportionating the salt. Rogers showed the same occurrence with 
lidocaine oleate ionic liquids. Only when the sample was measured using solid state NMR at a 
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temperature of 80° C did shifts become evident
29
. Solution state proton NMR is therefore, not a 
robust method of confirming salt formation. Other techniques that maintain the phase of the 
material are better suited for AIL characterization.  NMR can be utilized to determine purity of 
AIL samples
12
. Solvents and unwanted reaction byproducts may be detected in the spectra, 
indicating further purification is needed.  
 
Residual Solvent 
The amount and identity of residual solvents in an active ionic liquid sample could have 
repercussions on a number of properties. The discrepancy between KF and TGA residual solvent 
amounts in the lidocaine salicylate sample may be due to the viscous nature of the sample 
causing solvent to become trapped within the liquid; and therefore, more slowly vaporized by the 
increasing temperatures in the TGA. Instead of a standard temperature ramp method for the TGA, 
an isothermal hold at an elevated temperature until the weight stabilizes would provide a rate and 
total amount of solvent loss without nearing the decomposition temperature. Karl Fisher titration 
for water is a better method, but not available on a routine basis. Assuming the solvent is water, 
it may play in important role in the physical properties of the liquid. It is a common occurance 
that solvent impurities lower the glass tranistion temperatures of material
3
.  The residual solvent 
would also manifest itself in the higher viscosity of the mandelate and malate salts of lidocaine 
over the benzoate salt. Mandelic acid and malic acid have increasing numbers of hydrogen 
bonding sites over benzoic acid. Mandelic acid has an additional hydoxy group and malic acid 
has two carboxylic acids and a hydroxyl group available for hydrogen bonding. Hydrogen 
bonding may be why the ketoprofen malate, mandelate, and tosylate samples were metastable in 
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the liquid phase. H-bonding between the two acids and the solvent may facilitate the liquid phase 
stability until the solvent evaporates fully.  
 
A remaining issue is how to keep AIL samples dry during storage and during further 
experimental preparations. Dessicated storage is feasible but once the container is opened to 
atmospheric moisture how does one remove the absorbed water to maintain a consistent dryness 
over time? It is more practical to dry as much as possible during preparation and then account for 
the remaining water in subsequent characterization. If new experiments are conducted 
weeks/months after the initial TGA, then that assay may need to be re-run. When using solvent 
extraction instead of a melt reaction, then the weight loss in the TGA cannot be assumed to be 
only water. GC and KF analysis would need to be conducted to quantify the amount of solvent 
and water present in the sample. 
 
The viscosity doesn't trend with grass transition, as well as expected.  Lidocaine manelate and 
malate ionic liquids have the same glass transition temperature of 3.3 and 3.2 °C, respectively. 
The viscosity of the mandelate salt at room temperature is an order of magnitude higher than the 
malate salt.  The residual solvent may be affecting the viscosity. The malate salt has about three 
times the amount of residual solvent by TGA as the mandelate salt. The plasticizing affect of the 
solvent may influence the viscosity to a higher degree than the Tg. An issue lies in the dispensing 
of AILS. Even the least viscous lidocaine benzoate is difficult to handle at room temperature or 
in the molten state.  The cohesivity of the liquid, (stickiness) can be compared again to honey.  
Regular or ad hoc dispensing of the compound is not practical and heated dispensing and mixing 
equipment is likely to be needed. An issue with slow mobility was apparent in the DVS data, 
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similar to the TGA results. The sorption plot for Lidocaine salicylate did not show significant 
water sorption until conditions greater than 80% RH (Figure 2). However, weight stabilization 
was not achieved within the designated 180 min before the between humidity increases, 
suggesting that the sample may be more hygroscopic than the experimental conditions can 
determine. The sample needs to be held at each humidity level for longer periods of time to 
better determine the hygroscopicity.   
 
Salt Factor 
The salt factor of the samples was determined by an HPLC analysis of the area of the parent 
active compound versus the area of the parent in the salt form.  All the samples were prepared 
with equal-molar amounts of parent and counterion.  Only the Propantheline tosylate sample was 
isolated with a filtration step to remove impurities and the silver bromide salt.  The other samples 
do not have a purification step to remove excess reagents, which will then contribute to the total 
area of the parent or counterion in the HPLC assay. The assay should determine that all samples, 
with the possible exception of Propantheline tosylate are mono-salts, regardless of the actual 
stoichiometry.  A case where the assay would be in error would be if the excess acid or base was 
soluble in the few percentage of solvent remaining in the sample or soluble in the ionic liquid 
itself.  Ionic liquids were used as solvents for a number of years
4
.  Literature references have 
shown that ionic liquids can be formed with greater than molar equilivants of active and 
therefore, presumably counterion
30
.   
 
Lidocaine mandelate's assay value corresponds to a hemi-salt.  Two active ions share one proton. 
Based on the preceding discussion on the limitations of the assay, it is unknown exactly how this 
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result corresponds to the expected outcomes of the reaction. The most likely scenario is a 
weighing error during sample preparation, but was not confirmed through re-synthesis. Since the 
IR data supports proton transfer, an orthogonal method for accurately determining stoichiometry 
of the salt is needed.  Propantheline tosylate is measured to be between a mono and a bis-salt.  
Based on the included filtration step in preparing this sample, incomplete filtration is likely the 
issue, with excess tosylate remaining in the sample. A possible confirmation experiment for this 
sample would be a sulfur-based elemental analysis assay. MK-A tosylate salt has a low area 
count for the parent compound.  Degradation was not noted in the assay. A sample weighment 
error is the likely cause of the low area, which then caused the percentage of parent in the sample 
to be in order of magnitude different than the calculated percentage for a mono-salt. MK-A 
citrate has a percentage of parent compound in the sample that more closely corresponds to a 
hemi-salt than a mono-salt.  Ketoprofen mandelate has 11% error between the measured and 
calculated parent percentage in the sample, corresponding to the non-ionic nature of the bonding 
for this metastable liquid. 
 
Solubility 
Significant solubility increases of the AIL over their free base solubility was not observed for all 
samples. The solubility of the lidocaine ionic liquids did increase in aqueous media compared to 
the free base.  In FaSSIF, the solubility increased from 11.7 mg/mL as the free base to 32.2 
mg/mL as the salicylate salt ionic liquid, while maintaining the ionic liquid phase. Solubility was 
not increased in the MK-A ionic liquids when compared to free base.  They likely 
disproportionated to the parent form, though this was untested. Ketoconazole free base solubility 
is needed to determine if there are differences upon liquid salt formation.  
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Conclusion 
A medium throughput screen was developed for the formation of active ioninc liquids. The 
reproducibility of the hits upon scale up was typical for phase screening. The addition of more 
counterions and active compounds to the data set is needed, but proof of concept has been 
established.  AILs can be screened by the same methods as conventional crystalline salts. 
Hopefully the “oil” wells in existing high throughput salt screens will not be rejected, but scaled 
up as potential AILs.  Identification via IR and analysis of glass transition, residual solvent, salt 
factor and biorelevant solubility were conducted for a number of novel AILs of generic and 
propriatary compounds. While the equilibrium solubility enhancement of AILs over their neutral 
forms was not as high as hoped for, the kinetic advantage and utility for liquid dosing remains to 
be investigated. Ultimately, until preclinical species in vivo exposure data of an AIL is compared 
to the crystalline salt form and a collection of high POS ions is determined, the actual utility of 
AILs to drug development cannot be determined. 
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Appendix A: Thermogravmetric Analysis (TGA) 
 
 
 
Figure A1. Lidocaine salicylate batches 2, 3, and 3b TGA spectra overlay. 
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Figure A2. Lidocaine salicylate (3b), benzoate, mandelate, malate, fumarate, tosylate, and 
nicotinate TGA speactra overlay. 
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Figure A3.  MK- C tosylate, mandelate, malate, citrate, and benzoate TGA spectra overlay.  
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Figure A4.  MK- A glutamate, MK- A mesyltae, MK- A salicylate, MK-B tosylate, Itraconazole 
tosylate, Acetominophine tosylate, and Propantheline tosylate TGA spectra overlay. 
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Figure A5.  Ketoprofen malate, tosylate, and mandelate TGA spectra overlay.   
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Figure A6. Ketoconazole citrate, malate, tosylate, and mandelate TGA spectra overlay.   
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Figure A7. MK- E tosylate, benzoate, citrate, malate, and mandelate TGA spectra overlay.  
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Figure A8. Lidocaine, Propantheline Br, Merck C, Merck E, Ketoprofen and Ketoconazole 
parent compound standard TGA spectra overaly.  
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Appendix B: Modulated Differential Scanning Calorimetry 
(mDSC)
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Figure B1. Lidocainium salicylate batch 1 (blue), batch 2 (pink), batch 3 (maroon) and batch 3b 
(red) mDSC overlay with cycle 1 glass transition temperature indicated.  
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Figure B2.  Propantheline tosylate (red) and MK-B tosylate (blue) mDSC overlay with cycle 1 
glass transition temperature indicated. 
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Figure B3. Ketoconazole tosylate (green), ketoconazole mandelate (blue), and ketoconazole 
citrate (red) mDSC overlay with cycle 1 glass transition temperature indicated. 
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Figure B4. Ketoconazole malate mDSC with cycle 1 glass transition temperature indicated.  
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Figure B5. Ketoprofen malate (green), tosylate (blue) and mandelate (red) mDSC overlay with 
cycle 1 glass transition temperature indicated. 
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Figure B6. MK-C benzoate (blue), citrate (maroon), malate (red), mandelate (silver), and tosylate 
(pink) mDSC overlay with cycle 1 glass transition temperature indicated. 
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Figure B7. MK-E citrate (pink), malate (red), mandelate (silver), tosylate (blue), and benzoate 
(green) mDSC overlay with cycle 1 glass transition temperature indicated. 
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Appendix C: Dynamic Vapor Soption (DVS) 
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Figure C1. Lidocaine salicylate batch 3 DVS weight % and measured relative humidity vs. time 
plotted. 
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Figure C2. Lidocaine benzoate DVS relative humidity vs. weight change % plot. 
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Figure C3. Propanteline tosylate DVS weight % and measured relative humidity vs. time plotted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
 
Appendix D: Nuclear Magentic Resonance (NMR)  
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Figure D1.  Lidocaine Standard NMR 
 
 
Figure D2.  Salicylic acid standard NMR 
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Figure D3. Lidocaine salicylate batch 3 NMR  
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Figure D4. Propantheline Bromide standard NMR 
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Figure D5.   p-Toluenesulfonic Acid standard NMR 
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Figure D6. Propantheline tosylate NMR  
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Figure D7.  Lidocaine Benzoate NMR, ranging form 0 – 3.5 ppm 
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Figure D8.  Lidocaine Benzoate NMR ranging from 3.5-7.5 ppm 
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Figure D9. Lidocaine Benzoate NMR ranging from 7 – 11.5 ppm 
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Figure D10. Lidocaine Mandelate NMR 
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Figure D11.  Lidocainae malate NMR 
Appendix E: Viscosity 
Lid-Sa Batch 3 Viscosity at Increasing Temperatures
1
10
100
1000
10000
100000
1000000
0.1 1 10 100 1000
Rotation Rate (rad/s)
V
is
c
o
s
it
y
 (
P
a
*
s
)
22C 40C 60C 80C
 
Figure E1. Lidocaine salicylate Batch 3 Viscosity vs. Temperature  
 
 
Figure E2. Lidocaine benzoate Viscosity vs. Temperature 
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Figure E4. Lidocaine Mandelate Viscosity vs. Temperature 
 
 
Figure E5. Lidocaine Malate Viscosity vs. Temperature 
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Appendix F: X-ray Diffraction (XRD) 
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Figure F1. XRD overlay of MK-A acetate (pink), MK-A glutamate (red), MK-A MSA (purple), 
MK-A nicotinate (brown), MK-A salicylate (teal), and MK-A standard (green).  
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Figure F2. Lidocaine with Fumaric acid sample, lidocaine standard XRD pattern.  
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Figure F3. Lidocaine with nicotinic acid sample and lidocaine standard XRD pattern.  
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Figure F4. Lidocaine tosylate, lidocaine standard and tosylate standard XRD pattern.  
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Appendix G: Fourier Transform Infrared Spectroscopy (FTIR) 
 
Figure G1 . Lidocaine salicylate (red), lidocaine standard (black), and salicylic acid standard 
(blue) IR spectra.  
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Figure G2. Lidocaine standard (red), benzoic acid standard (black), and Lidociane benzoate 
(blue) IR spectra 
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Figure G3. Lidocaine mandelate (black), Lidocaine standard (blue), and mandelic acid standard 
(red) IR spectra. 
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Figure G4. Lidocaine Malate (black), Lidocaine standard (blue) and malic acid standard (red) IR 
spectra. 
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Figure G5. Lidocaine with nicotinic acid solids (black) and lidocaine standard (blue) IR spectra. 
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Figure G6. Lidocaine with Fumaric acid sample IR spectra. 
 
